Short answer
Foghorn Therapeutics Inc. (FHTX) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Foghorn reported financial results for the quarter ended June 30, 2026.
Foghorn Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Foghorn reported financial results for the quarter ended June 30, 2026
- Press release issued August 6, 2026; detailed figures provided in Exhibit 99.1
- Results announcement gives investors an updated view of liquidity, operating performance, and development funding needs
Item 7.01 · Regulation FD Disclosure
- August 2026 investor presentation furnished as Exhibit 99.2 under Regulation FD
- Presentation likely contains updated investor-facing business, pipeline, or corporate information
- Investors should review Exhibit 99.2 for substantive disclosures and potential outlook changes
Item EX-99.1 · Exhibit EX-99.1
- Q2 collaboration revenue $16.1M vs $7.6M, boosted by $14.2M cumulative catch-up tied to Lilly research-term expiration
- Net loss narrowed to $7.2M from $17.9M, while R&D fell to $18.5M from $21.8M
- FHD-909 Phase 1 dose escalation remains on track, with NSCLC as the primary target population
- Selective EP300 degrader and oral immunology program target IND filings in 2027
- Cash, equivalents and marketable securities totaled $167.6M, supporting runway into the first half of 2028
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Foghorn Therapeutics Inc. 8-K filings
Get the next FHTX 8-K as it lands
Follow FHTX for push alerts, or ask the research agent what this filing means.